Hematologic Malignancy Center Faculty / Medical Staff >

At the Hematologic Malignancy Center, specialists come together from the Division of Hematology and Oncology, the Department of Laboratory Medicine and Genetics, the Department of Pathology, and the Department of Radiation Oncology and provide the best possible and most recent treatment for hematologic malignancy like lymphoma and multiple myeloma. Our goal is to become the best hematologic malignancy center in Asia both for our patients and colleagues by offering the most appropriate treatment and continuing cutting-edge clinical and basic research.

Major areas of treatment / Clinics

Acute and chronic leukemia, anemia aplastic, Hodgkin's disease, non-Hodgkin's lymphoma, myelodysplastic syndrome, multiple myeloma, etc.

Strong points

  • The Center is developing new treatment methods including cytotherapy agents and participating in multinational clinical studies in various phases to introduce the latest medicines to Korea.
  • We guarantee the best patient care thanks to our multi-disciplinary treatment and diagnosis approach. The Division of Hematologic Malignancy Center focuses on the best possible care and research including new drug clinical trials, while the Department of Radiation Oncology is in charge of whole-body irradiation for stem cell transplantation and preventive whole-brain radiotherapies. The Department of Laboratory Medicine and Genetics works on lab tests such as bone marrow examination, chromosome analysis, FISH, and flow cytometry, and the Department of Pathology makes a diagnosis using the latest technology of immunopathology and molecular pathology.
  • The best nursing service is provided by our skilled inpatient and outpatient nurses, oncology nurse practitioners, transplantation coordinators, and research nurses.

Diagnostic tests

Basic blood testing, bone marrow examination, lymph node examination, CT, MRI, PET-CT, etc.

Latest treatment methods

  • Diverse and latest chemotherapies
  • Hematopoietic stem cell transplantation: allogeneic, autologous, cord blood, or mini
  • Immunotherapeutic and cytotherapeutic agents
  • New drug clinical trials

Recent trends in clinical research

We perform the best possible treatment and research including new drug clinical trials for hematologic malignancy. We are currently conducting a global multi-center alemtuzumab clinical study to apply it to mini-transplantation and minimize the risk of graft-versus-host diseases among acute myelogenous leukemia and myelodysplastic syndrome patients over 50. Also, we are applying dose-intensified chemotherapy to acute lymphoblastic leukemia as part of a domestic multi-center clinical study.

To treat chronic myelogenous leukemia, we are using both first- and second-generation Gleevec as a primary therapy, following global guidelines. At the same time, we are conducting global multi-center clinical trials to improve the therapy efficacy. Among them are comparison of Gleevec to nilotinib and radotinib and application of dasatinib depending on early molecular biological reactions to three-month Gleevec administration.

In case of multiple myeloma, the Center conducts international multi-center clinical trials of new drugs including Velcade and performs the latest stem cell transplantation such as autologous and mini-allogeneic stem cell transplantation. For patients with relapsing lymphoma, we clinically research new drugs and antibody therapies.

Departments List
CLOSE

Patients' Rights and Responsibilities

Patients' Rights

1. Right to receive medical care

Patients have the right to receive proper care in a safe setting without discrimination nor should their right to care be violated regardless of their gender, age, religion, social status, nationality, language, race, or physical/mental/financial status. Medical teams shall not refuse to provide care without justifiable reason.

2. Right to be informed and to make an autonomous decision

Patients have the right to obtain full and complete information from their medical team, to ask questions, and to determine their agreement or refusal concerning: diagnosis, treatment (purpose, plans and methods), outcomes of care (including unanticipated outcomes), discharge plan, participation in medical research studies, organ transplantation/donation, etc. Within ethical boundaries, patients may discontinue or refuse treatment, request that the medical team explain and suggest alternative treatments, and reserve the right to make their own decisions.

3. Right to confidentiality

Patients' rights to confidentiality regarding their physical/health status and privacy will not be violated. Patients can expect that all medical records/reports and their personal privacy will be kept confidential unless the patient has given consent or disclosure is permitted by law. To ensure their privacy, patients may be informed that Individuals not directly involved in their care may not be present and that the number of guardians accompanying patients to consultation rooms may be limited.

4. Right to request consultation and mediation

In the event of a medical dispute, patients may request consultation and mediation from an internal or external agency (Korea Consumer Agency, Korea Medical Dispute Mediation and Arbitration Agency).

5. Right to have values and beliefs respected

Patients will not be discriminated against because of their culture, religious values, or beliefs, and their rights will not be violated.

6. Right to receive care in a safe setting

Patients have the right to receive hospital-provided care where the patient’s medical information is protected and patient safety can be assured. In addition, patients have the right to be protected from possible dangers that can occur in a hospital and to have stability of mind and body.

Patients' Responsibilities

1. Responsibility to trust and respect the medical team

Patients must accurately inform the medical team of their health condition and must trust and respect the medical team's treatment plan. Patients may be responsible for consequences that result from not following instructions.

2. Responsibility to not use dishonest methods for medical treatment

Patients must reveal their identity before receiving any medical care and must not use false or dishonest methods, such as seeking medical care under disguised ownership.

3. Responsibility to abide by all hospital regulations

Patients are expected to treat all hospital staff and other patients with courtesy and respect; to abide by all hospital rules; and to earnestly fulfill their financial obligation to the hospital. Also, patients and their family members are expected to participate in all safety regulations.